Q32 BioFRA:DB0 -0.18%17 Return-on-Tangible-Equity is -69.34% as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,195 Biotechnology companies, Q32 Bio ranks better than 98.33% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Q32 Bio's annualized net income for the quarter that ended in Mar. 2026 was €-26.33 Mil. Q32 Bio's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €37.97 Mil. Therefore, Q32 Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -69.34%.
The historical rank and industry rank for Q32 Bio's Return-on-Tangible-Equity or its related term are showing as below:
FRA:DB0'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 125.06 Med: 125.06 Max: 309.93
Current: 309.93
During the past 5 years, Q32 Bio's highest Return-on-Tangible-Equity was 309.93%. The lowest was 125.06%. And the median was 125.06%.
FRA:DB0's Return-on-Tangible-Equity is ranked better than 98.33% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs FRA:DB0: 309.93
Q32 Bio (FRA:DB0) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Q32 Bio Return-on-Tangible-Equity Related Terms
Q32 Bio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Q32 Bio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DB0 vs CAMP, CDXS, KROS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Q32 Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Q32 Bio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -69.34% mean?
Q32 Bio (FRA:DB0) has a Return-on-Tangible-Equity of -69.34% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Q32 Bio and its competitors. Over the past decade, Q32 Bio's Return-on-Tangible-Equity has ranged from 125.06 to 309.93. According to the industry distribution chart, Q32 Bio ranks #20 out of 1195 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Q32 Bio's Return-on-Tangible-Equity too high?
Q32 Bio's current Return-on-Tangible-Equity is -69.34%. Over the past 10 years, this metric has ranged from a low of 125.06 to a high of 309.93. Based on the distribution chart, Q32 Bio ranks #20 out of 1195 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Return-on-Tangible-Equity compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #20 out of 1195 companies for Return-on-Tangible-Equity. This places Q32 Bio in the top 2% of its industry — outperforming the majority of peers. Historically, Q32 Bio's own Return-on-Tangible-Equity has ranged from 125.06 to 309.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Q32 Bio and its competitors. Q32 Bio's current Return-on-Tangible-Equity is -69.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Return-on-Tangible-Equity of -69.34%. The current Return-on-Tangible-Equity is -69.34%. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Return-on-Tangible-Equity is -69.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for FRA:DB0
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
